Effect and clinical significance of GnGHa therapy on serum levels of P1NP, β-CTX and N-MID in idiopathic central precocious puberty girls

doi:10.11852/zgetbjzz2017-25-12-28

Abstract

Abstract: Objective To investigate the effect of gonadotropin-releasing hormone analogue (GnRHa) on serum levels of P1NP,β-CTX,N-MID level in idiopathic central precocious puberty (ICPP) girls. Methods Totally 102 cases of ICPP girls in the Affiliated Hospital of the Armed Police Logistics college hospital were selected as the subjects,and were treated with GnRHa.The growth condition,hormone level and bone metabolism before and after treatment were compared. Results BMI and the level of PAH after treatment were significantly higher than those before treatment,and the volume of uterus and ovarian decreased significantly (P<0.05);The level of P-LH,P-FSH,E2 after treatment were significantly reduced than those before treatment (P<0.05);There was no significant difference on the β-CTX level between before and after treatment (P>0.05),and the level of P1NP,N-MID were significantly reduced than those before treatment (P<0.05). Conclusion GnRHa is an effective therapy on the treatment of ICPP girls,and can significantly improve the body hormone level,inhibit osteoblast function,and improve bone metabolism.

Key words: gonadotropin releasing hormone analogue, idiopathic central precocious puberty, girls, bone metabolism

摘要： 目的分析促性腺激素释放激素类似物(GnRHa)对特发性中枢性性早熟(ICPP)女童血清P1NP、β-CTX、N-MID水平的影响。方法选取本院102例ICPP女童作为研究对象,予以GnRHa治疗,对比治疗前后生长发育情况、激素水平、骨代谢水平。结果治疗后的BMI、PAH水平较治疗前显著升高,而子宫容积、卵巢容积显著变小,差异有统计学意义(P＜0.05);治疗后的P-LH、P-FSH、E2水平较治疗前显著降低,差异有统计学意义(P＜0.05);治疗前后的β-CTX水平无显著差异(P＞0.05),而P1NP、N-MID水平较治疗前显著降低,差异有统计学意义(P＜0.05)。结论 GnRHa在治疗ICPP女童方面疗效显著,可显著改善机体激素水平,抑制成骨细胞功能,改善患儿骨代谢水平。

关键词: 促性腺激素释放激素类似物, 特发性中枢性性早熟, 女童, 骨代谢

CLC Number:

R179

WANG Yan-hua, ZHAO Xin. Effect and clinical significance of GnGHa therapy on serum levels of P1NP, β-CTX and N-MID in idiopathic central precocious puberty girls[J]. journal1, 2017, 25(12): 1288-1289.

王琰华, 赵忻. GnGHa治疗对特发性中枢性性早熟女童血清P1NP、β-CTX、N-MID水平的影响及其临床意义[J]. 中国儿童保健杂志, 2017, 25(12): 1288-1289.

0
/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://manu41.magtech.com.cn/Jwk_zgetbjzz/EN/10.11852/zgetbjzz2017-25-12-28

https://manu41.magtech.com.cn/Jwk_zgetbjzz/EN/Y2017/V25/I12/1288

References

[1] 李燕虹,朱顺叶,马华梅,等.促性腺激素释放激素类似物联合司坦唑醇治疗改善大骨龄特发性中枢性性早熟女孩成年身高的疗效评价[J].中华儿科杂志,2013,51(11):807-812.
[2] 赵岫,张琴.来曲唑治疗特发性中枢性性早熟男童的临床观察[J].中国当代儿科杂志,2014,16(4):397-400.
[3] 陈瑞敏,蔡春艳,胡志坚,等.福建地区女童特发性中枢性性早熟危险因素分析[J].中华实用儿科临床杂志,2014,29(20):1543-1547.
[4] 杨丽珍,张巍,侯秀刚,等.栀早颗粒对肝郁痰结型特发性中枢型性早熟女童血清骨钙素的影响[J].吉林中医药,2013,33(2):162-164.
[5] 陈丽娜,向承发.促性腺激素释放激素类似物对特发性中枢性性早熟女童成人终身高的影响[J].现代预防医学,2013,40(23):4323-4325.
[6] 林翠兰,韦婉俭,何婉懿,等.促性腺激素释放激素类似物对特发性中枢性性早熟女童促生长素轴与生长速度的影响[J].中国儿童保健杂志,2016,24(1):65-68.
[7] 许文萍,余亮,谢磊,等.醋酸曲普瑞林治疗特发性中枢性性早熟女童的短期疗效评估[J].贵州医药,2016,40(5):495-497.
[8] 张龙江,冼雄辉,加子珍,等.促性腺激素释放激素类似物对特发性中枢性性早熟女童糖脂代谢的影响[J].中华实用儿科临床杂志,2013,28(20):1552-1554.
[9] 王蔚华,向楠.知柏合剂治疗女童特发性中枢性性早熟43例临床分析[J].中国妇幼保健,2016,31(4):852-853.
[10] 余丽蓉,杨玉,吴限,等.特发性中枢性性早熟儿童治疗前后胰岛素抵抗相关性研究[J].中国妇幼保健,2013,28(4):623-625.
[11] 谢理玲,杨玉,胡云,等.特发性中枢性性早熟女童干预治疗对体质量指数的影响[J].中华实用儿科临床杂志,2016,31(8):592-595.
[12] 王爱萍.曲普瑞林治疗女童特发性中枢性性早熟52例[J].中国药业,2013,22(9):59-60.
[13] 吴静,吕瑞丽,何春风,等.不同治疗方法对特发性中枢性性早熟女童初潮年龄及成年终身高的影响[J].中国妇幼保健,2014,29(36):6032-6034.
[14] 金献江,罗越,吴慧平,等.促性腺激素释放激素类似物对特发性中枢性性早熟女童体质指数及骨代谢标志物水平的影响[J].中国全科医学,2016,19(9):1049-1052.
[15] 刘亚军,庞敏,黄丽敏,等.促性腺激素释放激素类似物联合司坦唑醇对特发性中枢性性早熟女性患儿的身高影响[J].中国现代医学杂志,2014,24(34):86-89.